Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Tags Health & Science Pharmaceuticals US: News
From CNBC.com News
5 things to know before the stock market opens Monday
Tags Technology Business Biogen Inc
From CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Tags Health care industry Biogen Inc Business
From CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Tags Biotechnology Biotech and Pharmaceuticals Eisai Co Ltd
From CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
Tags Science Business News Eisai Co Ltd
From CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Tags Eisai Co Ltd Science Business News
From CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
Tags Eisai Co Ltd Business News Investment Strategy
From CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Tags US: News Earnings Pharmaceuticals
From CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Tags Companies Business Biogen Inc
From CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Tags Health care industry Healthy Returns Biogen Inc
From CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Tags US: News Earnings Health & Science
From CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Tags Health & Science Pharmaceuticals Social issues
From CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Tags Biotechnology Biotech and Pharmaceuticals Eisai Co Ltd
From CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Tags Companies Health care industry Abbott Laboratories
From CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Tags Pharmaceuticals Health & Science US: News
From CNBC.com News
5 things to know before the stock market opens Tuesday
Tags Technology Biogen Inc Business
From CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
Tags Health & Science Pharmaceuticals Eli Lilly and Co
From CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
Tags Social issues US: News U/S/ Economy
From CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Tags Companies Health care industry Business
From CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
Tags Finance Eisai Co Ltd Economy
From CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
Tags Pharmaceuticals Biogen Inc World Markets
From CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Tags US: News Social issues Health & Science
From CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
Tags Eisai Co Ltd Science Business News
From CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
Tags U/S/ Economy Politics Policy
From CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
Tags Health & Science Policy Politics
From CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
Tags US Top News and Analysis Politics U/S/ Economy
From CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Tags US: News US Economy Quanterix Corp
From CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
Tags Business Biogen Inc Pandemics
From CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Tags Breaking news Companies Biogen Inc
From CNBC.com News
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
Tags Pharmaceuticals Health & Science Eli Lilly and Co
From CNBC.com News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.